The iShares Biotechnology ETF carries a lower expense ratio and significantly larger assets under management (AUM) than the Simplify Health Care ETF.
The Simplify Health Care ETF provides broader exposure across healthcare sub-sectors and a higher dividend yield than the biotechnology-focused iShares fund.
While the iShares Biotechnology ETF has delivered a higher 1-year total return, the Simplify Health Care ETF has experienced a shallower maximum drawdown.
Investors choosing between the Simplify Health Care ETF (NYSEMKT:PINK) and iShares Biotechnology ETF (NASDAQ:IBB) must weigh the Simplify fund’s active management and broader healthcare focus against the iShares fund’s lower fees and concentrated biotech exposure.
The iShares Biotechnology ETF tracks a market-cap-weighted index of U.S. biotechnology stocks, offering high-conviction exposure to the sector. In contrast, the Simplify fund is an actively managed ETF targeting a wider array of medical innovation while pledging its net profits to the Susan G. Komen foundation.
| Metric | IBB | PINK |
|---|---|---|
| Issuer | iShares | Simplify |
| Share price | $204.56 (as of 2026-09-18) | $38.82 (as of 2026-09-18) |
| Expense ratio | 0.44% | 0.51% |
| 1-yr return (as of 2026-09-18) | 42.7% | 23.9% |
| Dividend yield | 0.2% | 0.6% |
| Beta | 0.70 | 0.73 |
| AUM | $10.5 billion | $359.8 million |
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
The iShares fund is slightly more affordable with a 0.44% expense ratio, compared to 0.51% for the Simplify fund. Investors seeking income may prefer the Simplify fund, which provides a higher payout compared to its biotechnology peer.
| Metric | IBB | PINK |
|---|---|---|
| Max drawdown (4 yr) | (24.8%) | (18.8%) |
| Growth of $1,000 over 4 years (total return) | $1,698 | $1,594 |
The Simplify Health Care ETF provides diversified exposure to healthcare sub-sectors like gene therapy and med-tech, with 91% of the fund in healthcare and small tilts toward industrials and consumer cyclicals. The portfolio holds 58 securities, and its largest positions include Lilly Eli + Co (NYSE:LLY) at 9.81%, Humana Inc (NYSE:HUM) at 7.09%, and Arcutis Biotherapeutics (NASDAQ:ARQT) at 6.47%. It was launched in 2021 and utilizes a currency hedge. Simplify Health Care ETF has paid $0.25 per share over the trailing 12 months, which on its recent ~$38.82 share price works out to a 0.6% yield.
The iShares Biotechnology ETF is a pure-play healthcare fund with 100% exposure to the sector, primarily through biotechnology stocks. Its largest positions among its 244 holdings include Gilead Sciences (NASDAQ:GILD) at 8.37%, Vertex Pharmaceuticals (NASDAQ:VRTX) at 7.61%, and Amgen Inc (NASDAQ:AMGN) at 7.31%. It was launched in 2001 and has no specific quirks like hedging. iShares Biotechnology ETF has paid $0.34 per share over the trailing 12 months, which on its recent ~$204.56 share price works out to a 0.2% yield.
For more guidance on ETF investing, check out the full guide at this link.
Healthcare stocks offer plenty of upside potential, given the possibilities for scientific breakthroughs. The iShares Biotechnology ETF (IBB) and the Simplify Health Care ETF (PINK) offer two unique ways to gain that exposure. Deciding which to choose depends on the factors that matter most to you.
PINK is a newer fund that offers a superior dividend yield compared to IBB. Its expense ratio is higher because it is an actively-managed ETF, with a vehicle that donates management fees to the Susan G. Komen Foundation. So your costs are contributing to the fight against breast cancer. It focuses on biotech, medtech, gene therapy, and other fast growing healthcare-related sectors that can deliver new treatments to solve health concerns.
IBB targets biotech companies specifically, and that has contributed to a strong 42.7% one-year return. Its much larger AUM provides better liquidity, and its greater number of holdings offer diversification. That said, its narrow sector focus and heavy weighting toward mega-cap stocks means performance can suffer if these companies experience a downturn.
Before you buy stock in Simplify Exchange Traded Funds – Simplify Health Care ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Simplify Exchange Traded Funds – Simplify Health Care ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $386,781!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,379,943!*
Now, it’s worth noting Stock Advisor’s total average return is 936% — a market-crushing outperformance compared to 213% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 25, 2026.
Robert Izquierdo has positions in Amgen. The Motley Fool has positions in and recommends Amgen, Eli Lilly, Gilead Sciences, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
